Trial · NCT00729430
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
NCT00729430, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2017-06-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging. Trials, record NCT00729430. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00729430
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
- NCT number
- NCT00729430
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 358 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Myocardial Infarction, Death, Sudden, Cardiac
- Interventions
- Omega-3 Fatty Acids (Fish Oil Supplements), Placebo
- First posted
- 2008-08-07
- Last updated
- 2017-06-01
- Results first posted
- 2017-06-01
- Limitations and caveats
The study was not powered to evaluate for clinical heart failure and hard cardiac outcomes. A prospective trial would be necessary to determine the effect of earlier and high-dose omega-3 fatty acid therapy on improving clinical outcomes.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling | Before and after study treatments | Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months) |
| Secondary | Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis | Measured in the 3-year follow-up period after participant's last study visit | Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months) |
| Secondary | Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction | Measured in the 3-year follow-up period after participant's last study visit | Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months) |
| Secondary | Effect of Omega-3 Fatty Acids on Infarct Size | Measured in the 3-year follow-up period after participant's last study visit | Measured as change in infarct size from baseline to post-treatment (6-months) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling | Before and after study treatments | Percent Change | MEAN | |
| SECONDARY | Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis | Measured in the 3-year follow-up period after participant's last study visit | Percent Change | MEAN | |
| SECONDARY | Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction | Measured in the 3-year follow-up period after participant's last study visit | Percent Change | MEAN | |
| SECONDARY | Effect of Omega-3 Fatty Acids on Infarct Size | Measured in the 3-year follow-up period after participant's last study visit | Percent Change | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling | High Dose Omega-3 Fatty Acid Arm | -5.4 | Standard Deviation 16.6 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling | Placebo Arm | 1.2 | Standard Deviation 20.9 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis | High Dose Omega-3 Fatty Acid Arm | -2.1 | Standard Deviation 14 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis | Placebo Arm | 3.4 | Standard Deviation 15 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction | High Dose Omega-3 Fatty Acids Arm | 4.8 | Standard Deviation 11 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction | Placebo Arm | 2.1 | Standard Deviation 12 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Infarct Size | High Dose Omega-3 Fatty Acids Arm | -8.8 | Standard Deviation 39.9 | Percent Change | |
| Effect of Omega-3 Fatty Acids on Infarct Size | Placebo Arm | -1.9 | Standard Deviation 57.7 | Percent Change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | High Dose Omega-3 Fatty Acid Arm | 180 | |
| Overall Study | STARTED | Placebo Arm | 178 | |
| Overall Study | COMPLETED | High Dose Omega-3 Fatty Acid Arm | 133 | |
| Overall Study | COMPLETED | Placebo Arm | 128 | |
| Overall Study | NOT COMPLETED | High Dose Omega-3 Fatty Acid Arm | 47 | |
| Overall Study | NOT COMPLETED | Placebo Arm | 50 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fishy Taste in Mouth | Gastrointestinal disorders | High Dose Omega-3 Fatty Acids Arm | 8 | 180 | 8 |
| other | Fishy Taste in Mouth | Gastrointestinal disorders | Placebo Arm | 2 | 178 | 2 |
| other | Nausea | Gastrointestinal disorders | High Dose Omega-3 Fatty Acids Arm | 10 | 180 | 10 |
| other | Nausea | Gastrointestinal disorders | Placebo Arm | 9 | 178 | 9 |
| serious | Allergic Reaction (Tongue Swelling) | Immune system disorders | High Dose Omega-3 Fatty Acids Arm | 1 | 180 | 1 |
| serious | Allergic Reaction (Tongue Swelling) | Immune system disorders | Placebo Arm | 0 | 178 | 0 |
| serious | Bleeding | Blood and lymphatic system disorders | High Dose Omega-3 Fatty Acids Arm | 0 | 180 | 0 |
| serious | Bleeding | Blood and lymphatic system disorders | Placebo Arm | 0 | 178 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | High Dose Omega-3 Fatty Acids Arm | ||
| Total, all-cause mortality | Placebo Arm | ||
| Total, other adverse events | High Dose Omega-3 Fatty Acids Arm | 18 | 180 |
| Total, other adverse events | Placebo Arm | 11 | 178 |
| Total, serious adverse events | High Dose Omega-3 Fatty Acids Arm | 1 | 180 |
| Total, serious adverse events | Placebo Arm | 0 | 178 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HL091157 | Prognostic Impact and Arrhythmic Potential of Peri-infarct Zone by Cardiac MRI | KWONG, RAYMOND Y | BRIGHAM AND WOMEN'S HOSPITAL | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2008 to 2012 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| High Dose Omega-3 Fatty Acids Arm vs Placebo Arm: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00729430
GET https://conductscience.org/api/trials/v1/NCT00729430/registered